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Abstract: A number of 1,2-benzothiazines have been synthesized in a three-step process. Nine 
chalcones 1–9 bearing methyl, fluoro, chloro and bromo substituents were chlorosulfonated with 
chlorosulfonic acid to generate the chalcone sulfonyl chlorides 10–18. These were converted to the 
dibromo compounds 19–27 through reaction with bromine in glacial acetic acid. Compounds 19–27 
were reacted with ammonia, methylamine, ethylamine, aniline and benzylamine to generate a 
library of 45 1,2-benzothiazines 28–72. Compounds 28–72 were evaluated for their antimicrobial 
activity using broth microdilution techniques against two Gram-positive bacteria (Bacillus subtilis 
and Staphylococcus aureus) and two Gram-negative bacteria (Proteus vulgaris and Salmonella 
typhimurium). The results demonstrated that none of the compounds showed any activity against 
Gram-negative bacteria P. vulgaris and S. typhimurium; however, compounds 31, 33, 38, 43, 45, 50, 
53, 55, 58, 60, 63 and 68 showed activity against Gram-positive bacteria Bacillus subtilis and 
Staphylococcous aureus. The range of minimum inhibitory concentration (MIC) and minimum 
bactericidal concentration (MBC) was 25–600 µg/mL, though some of the MIC and MBC 
concentrations were high, indicating weak activity. Structure activity relationship studies revealed 
that the compounds with a hydrogen atom or an ethyl group on the nitrogen of the thiazine ring 
exerted antibacterial activity against Gram-positive bacteria. The results also showed that the 
compounds where the benzene ring of the benzoyl moiety contained a methyl group or a chlorine 
or bromine atom in the para position showed higher antimicrobial activity. Similar influences were 
identified where either a bromine or chlorine atom was in the meta position. 
Keywords: 1,2-benzothiazines; chalcones; Bacillus subtilis; Staphylococcous aureus; Proteus vulgaris; 
Salmonella typhimurium 
 
1. Introduction 
The emergence of drug-resistant strains of bacteria is an increasing threat to society. Many 
antibiotics that were formerly effective in curing bacterial infections are no longer efficient because 
of the evolution of resistant strains. Therefore, there is an urgent need for a new class of antibacterial 
agents [1]. Clinically, antibiotic resistance is one of the greatest challenges of the 21st century. 
Antibiotic resistance has led to the emergence of superbugs such as methicillin-resistant 
Staphylococcus aureus and extremely resistant tuberculosis bacteria which are impossible to treat with 
available medicines [2,3]. New antibacterial agents are currently being developed at a much slower 
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pace than our growing need for such drugs. Amongst the family of heterocyclic compounds, those 
with nitrogen and sulfur atoms have been identified as having the most comprehensive spectrum of 
biological activities [4]. The biological and pharmacological properties of these compounds have been 
demonstrated in a number of studies [4,5]. 
Derivatives of benzothiazine have, depending upon the substituents present, shown biological 
activities that range from antipsychotic to anti-inflammatory [6–8]. The 1,2-benzothiazines have 
shown various biological activities such as anti-inflammatory [9], CNS depressant [10,11], anti-
depressants [12], anticancer [13] and antimicrobial [14]. They also act as potent calpain I inhibitors 
[15] and vasodilators [16]. Previous research has shown 1,2-benzothiazines to be potent antimicrobial 
agents against Gram-positive bacterial strains and fungal strains such as Aspergillus flavus, Aspergillus 
niger, Fusarium oxysporum [17]. In addition 1,2-benzothiazines have been seen to show marked 
activity against B. subtilis [17–20]. In recent years there has been a rapid growth in the literature 
pertaining to the benzothiazine ring system; much of this literature relates to the discovery that 3-
carboxamides of 2-alkyl-4-hydroxy-2H-1,2-benzothiazine-1,1-dioxides are anti-inflammatory agents, 
which includes the drugs piroxicam, ampiroxicam and meloxicam (Figure 1) [21–28]. The common 
route to these types of compounds is via the alkoxide rearrangement of saccharin derivatives (Scheme 
1) [29–35].  
 
Figure 1. Structures of 1,2-benzothiazine-based drugs. 
 
Scheme 1. Synthesis of 1,2-benzothiazines via the alkoxide rearrangement of saccharin derivatives. 
There are a number of different synthetic routes to 1,2-benzothiazines; however, the starting 
materials are not readily available. We recently developed a straightforward route to 1,2-
benzothiazines using readily available chalcones [36]. In light of these observations, a series of new 
1,2-benzothiazines were synthesized with the aim of obtaining potential antibacterial agents. 
2. Results 
2.1. Chemistry 
Synthetic target compounds 28–72 were synthesized in a three-step process outlined in Scheme 
2 in yields of 44%–96%. The chalcones 1–9, which were synthesized by reacting different 
acetophenones with 3,4-dimethoxybenzaldehyde following known literature methods [37–39], were 
reacted with chlorosulfonic acid at room temperature to generate the chalcone sulfonyl chlorides 10–
18. Melting points and spectral data (IR, 1H-NMR, 13C-NMR and nanoESI-MS) were consistent with 
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literature data (see supplementary data for 1H-NMR, 13C-NMR, HSMS of representative compounds). The 
sulfonyl chlorides 10–18 were deemed pure enough without recrystallization and reacted with 
bromine in glacial acetic acid at room temperature, which yielded the chalcone dibromo sulfonyl 
chlorides 19–27. Subsequently, the dibromo chalcone sulfonyl chlorides 19–27 were treated with 
ammonia and four primary amines (methylamine, ethylamine, aniline and benzylamine) to afford a 
benzothiazine library of 45 compounds 28–72. The structures of the newly synthesized 
benzothiazines 28–72 were appropriately characterized by spectral data. The IR spectra of 
compounds 28–72 confirmed the presence of the carbonyl signal in the region 1650–1720 cm−1 and all 
these compounds exhibited additional bands corresponding to the SO2 group (νmax 1340 and 1170 
cm−1). 
 
Scheme 2. Synthetic steps for compounds 10–18, 19–27 and 1,2-benzothiazines 28–72. 
Compounds 29, 34, 39, 54, 59, 64 and 69 formed when the dibromo chalcone sulfonyl chlorides 
were reacted with methylamine. The 1H-NMR of these compounds showed the presence of the 
methylamino group in the δ 2.2–2.8 region. The methine protons all appeared as doublet-of-doublets 
in all the 1,2-benzothizaines, as expected, with the exception of compound 48 which did not show 
peaks for the two methine protons. Compound 48 showed two singlets at δ 3.93 and δ 4.01 for the 
two methoxy groups and three singlets in the aromatic region between δ 6.86–7.84. A broad singlet 
at δ 8.20 was observed for the amino proton which was exchangeable with D2O. The definitive 
structure of compound 48 was confirmed by spectral and X-ray analysis with the ORTEP 
representation of the molecular structure shown in Figure 2b. 
 
(a) (b)
Figure 2. (a) Structure of (6,7-dimethoxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-3-yl)(4-fluoro-phenyl) 
methanone and (b) ORTEP diagram of 48.  
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2.2. Antimicrobial Screening 
The synthesized compounds 28–72 (Table 1) dissolved in DMSO were evaluated for their 
antimicrobial activity against bacterial strains of Bacillus subtilis ATCC 6633, Staphylococcous aureus 
ATCC 6538, Salmonella typhimurium ATCC 14028 (Salmonella enterica) and Proteus vulgaris ATCC 
13315 by determining their minimum inhibitory concentrations (MICs) using a micro-broth dilution 
technique and their minimum bactericidal concentrations (MBCs). Their activities were compared 
with those of the known antibacterial streptomycin. There was no inhibition of growth of any of the 
bacteria in the presence of DMSO up to 5% concentration; however, there was a slight decrease in 
absorbance between concentrations of 5% to 8%, but after 8% there was a steep decrease in absorbance 
showing inhibition of growth. 
The MICs and MBCs of selected compounds are presented against both Gram-positive and 
Gram-negative bacterial strains in Table 2. Results of the anti-bacterial activity showed that the MICs 
and MBCs of compounds (31, 33, 38, 43, 45, 50, 55, 58, 60, 63 and 68) varied between the ranges of 25–
600 µg/mL for B. subtilis. The MICs range of these compounds for S. aureus varied between 100–500 
µg/mL whereas only compounds 53, 58 and 60 showed a bactericidal effect in the range of 200–400 
µg/mL. None of the compounds showed any activity against the selected Gram-negative bacteria as 
MIC values were higher than 600 µg/mL. 
The MIC of most of the compounds that showed antimicrobial activity against bacterial species 
B. subtilis and S. aureus was quite high (400–600 µg/mL) as compared to streptomycin which has a 
MIC of 12.5 µg/mL for Gram-positive bacteria (Table 2), therefore showing very weak antibacterial 
activity as compared to streptomycin. Only compounds 33, 38, 43 and 58 showed MIC values between 
25–50 µg/mL for B. subtilis (see supplementary data Figures S1–S6). 
Table 1. The general structure of compounds 28–72 where R1, R2 and R3 refer to substituents attached 
to the benzoyl moiety while R4 and R5 refer to the substituents attached to the thiazine ring. 
Compound R1 R2 R3 R4 R5 
28 H H H H Br 
29 H H H CH3 NHCH3 
30 H H H CH2CH3 Br 
31 H H H Ph Br 
32 H H H PhCH2 Br 
33 CH3 H H H Br 
34 CH3 H H CH3 NHCH3 
35 CH3 H H CH2CH3 Br 
36 CH3 H H Ph Br 
37 CH3 H H PhCH2 Br 
38 Cl H H H Br 
39 Cl H H CH3 NHCH3 
40 Cl H H CH2CH3 Br 
41 Cl H H Ph Br 
42 Cl H H PhCH2 Br 
43 Br H H H Br 
44 Br H H CH3 Br 
45 Br H H CH2CH3 Br 
46 Br H H Ph Br 
47 Br H H PhCH2 Br 
48 F H H H H 
49 F H H CH3 Br 
50 F H H CH2CH3 Br 
51 F H H Ph Br 
52 F H H PhCH2 Br 
53 H Cl H H Br 
54 H Cl H CH3 NHCH3 
55 H Cl H CH2CH3 Br 
56 H Cl H Ph Br 
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57 H Cl H PhCH2 Br 
58 H Br H H Br 
59 H Br H CH3 NHCH3 
60 H Br H CH2CH3 Br 
61 H Br H Ph Br 
62 H Br H PhCH2 Br 
63 H H Cl H Br 
64 H H Cl CH3 NHCH3 
65 H H Cl CH2CH3 Br 
66 H H Cl Ph Br 
67 H H Cl PhCH2 Br 
68 H H Br H Br 
69 H H Br CH3 NHCH3 
70 H H Br CH2CH3 Br 
71 H H Br Ph Br 
72 H H Br PhCH2 Br 
Table 2. MIC and MBC (µg/mL) of selected compounds and streptomycin against Gram-positive 
bacteria B. subtilis, S. aureus and Gram-negative bacteria P. vulgaris, S. typhimurium and their Clog  
p-values (For MIC and MBC values in umol/ml see supplementary data Table S1)  
Compound 
B. subtilis S. aureus P. vulgaris S. typhimurium 
Clog P 
MIC MBC MIC MBC MIC MBC MIC MBC 
31 500 500 500 >600 >600 >600 >600 >600 4.668 
33 50 50 100 >600 >600 >600 >600 >600 3.316 
38 50 50 100 >600 >600 >600 >600 >600 3.596 
43 25 50 100 - >600 >600 >600 >600 3.746 
45 500 500 500 - >600 >600 >600 >600 4.811 
50 500 600 400 >600 >600 >600 >600 >600 4.091 
53 100 100 100 200 >600 >600 >600 >600 3.596 
55 100 100 200 >600 >600 >600 >600 >600 4.661 
58 25 50 100 200 >600 >600 >600 >600 3.746 
60 600 >600 400 400 >600 >600 >600 >600 4.811 
63 >600 >600 400 >600 >600 >600 >600 >600 3.336 
68 >600 >600 500 >600 >600 >600 >600 >600 3.486 
Streptomycin 12.5 12.5 12.5 25 6.25 6.25 100 100  
3. Discussion 
Prompted by the well-established antibacterial properties of benzothiazines, a series of 1,2-
benzothiazine derivatives, covering different modifications of the benzothiazine scaffold, were 
synthesized from readily available chalcones. The title compounds were assayed in vitro for the 
evaluation of their antimicrobial activity against Gram-positive and Gram-negative bacteria. 
The compounds with a hydrogen or an ethyl group on the nitrogen in the thiazine rings showed 
antibacterial properties against Gram-positive bacteria. The structure–antimicrobial activity 
relationship in the synthesized compounds revealed that 33, 38, 43, 53, 58, 63 and 68 inhibited the 
growth of Gram-positive bacteria. These compounds all contain a hydrogen atom on the nitrogen of 
the thiazine ring. This suggests that the amino group in the thiazine ring may be playing a role in the 
antibacterial property of these compounds. The results, therefore, support previous work which 
revealed that 4H-1,4-benzothiazines showed antibacterial activity against Gram-positive bacteria and 
fungi but no significant activity against Gram-negative bacteria [37]. In addition to this, compounds 
with an ethyl moiety on the nitrogen, 45, 50, 55 and 60, showed some inhibition of Gram-positive 
bacteria, though at higher concentrations. 
In previous work on 1,4-benzothiazines, it was noted that the presence of an extra nitrogen and 
oxygen atom increases the lipophilicity of the compounds [37]. They reported that in a series of 1,2-
benzothiazine-1,1-dioxides (N-methyl analogues), the compounds with greater lipophilicity 
possessed higher antibacterial activity. In the current work, compounds 29, 34, 39, 54, 59, 64 and 69 
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(N-methyl analogues) showed no activity, while 33, 38, 43, 53, 58, 63 and 68 showed weak 
antibacterial activity. These results are in contrast with the work of Ahmed and colleagues [37]. On 
the other hand, compounds 45, 50, 55 and 60 (N-ethyl analogues) showed some antibacterial activity 
which is in line with previous work [37]. 
The reaction of methylamine with the dibromo sulfonyl chlorides 19–27 unexpectedly resulted 
in the 4-methyamino derivatives 29, 34, 39, 54, 59, 64 and 69 which showed no antibacterial activity. 
However, the compounds with a bromine atom on carbon-4 in the thiazine ring displayed weak 
antibacterial activity, which would suggest that a bromine atom may be playing some role. This is 
supported by the fact that compound 48 did not show any antibacterial activity.  
The presence of different substituents in the benzene ring of the benzoyl moiety also had an 
effect on the antibacterial activity against B. subtilis. Compounds with a chlorine or bromine atom or 
a methyl group in the para position showed increased antibacterial activity and a bromine atom in 
the meta position gave similar results. Amongst the compounds which contain no substituents in the 
benzene ring, only 31 showed very weak antibacterial activity (MIC of 500 µg/mL for B. subtilis and 
S. aureus) while compounds 28–30 and 32 showed no activity. However, compounds substituted with 
methyl, chloro, bromo and fluoro substituents in the meta or para position showed inhibition for B. 
subtilis. The ortho-substituted compounds with the same substituents inhibited S. aureus weakly. 
In summary, the study conducted in this work has designed a simple synthetic route to 1,2-
benzothiazines from readily available starting materials. Some of the compounds (33, 38, 43, 45, 50, 
53, 55 and 58) synthesized, based on a library of 45 structures, showed some biological activity against 
Gram-positive bacteria B. subtilis and S. aureus, though the antibacterial activity was very weak as 
compared to the reference streptomycin standard. Based on our results, in vitro cytotoxicity work 
was not conducted for these compounds. 
4. Experimental 
4.1. General Information 
All chemicals were purchased form Sigma Aldrich ( St. Louis, MO, USA) and were used 
without any further purification. Melting points were determined using a Gallenkamp melting point 
apparatus (Thermo Fisher Scientific, Paisley, UK) and are uncorrected. The NMR spectra were 
recorded using a 600 MHz spectrometer (JEOL Co Ltd., Tokyo, Japan) with tetramethylsilane as 
internal standard and solvents as indicated. Chemical shifts were measured in ppm (δ) relative to 
TMS (0.00 ppm). Coupling constants (Ј) are reported in Hertz (Hz). The following abbreviations are 
used to describe the signal multiplicities: s (singlet), d (doublet), t (triplet), q (quartet) and m 
(multiplet). Accurate mass measurements were made at the National Mass Spectrometry Facility 
using Thermo Scientific LTQ Orbitrap XL with Advion Nanomate nanoelectrospray system 
(Waltham, MA, USA). Infrared spectra were recorded with a Varian spectrophotometer as KBr discs. 
TLC (thin layer chromatography) was performed using silica gel plates by dissolving the compound 
in dichloromethane and using the solvent system dichloromethane and diethyl ether. Clog P values 
were calculated using ChemBioDraw Ultra 13.0 (CambridgeSoft, Perkin Elmer, UK).  
4.2. Synthesis of Chalcones 
Chalcones 1–9 were synthesized by the well-established procedure using acetophenones and 
3,4-dimethoxybenzaldehyde [38]. 
4.3. General Procedure for the Synthesis of Chalcone Sulfonyl Chlorides 10–18 
The chalcones 1–9, (10 g; 0.032 mol) were added in portions to stirred chlorosulfonic acid (37.67 
g; 0.32 mol) in an ice bath. After the addition was complete the reaction mixture was left stirring at 
room temperature. Progress of the reaction was monitored by thin layer chromatography (TLC). 
When the reaction was complete (24 h), the mixture was poured slowly over ice to remove the excess 
chlorosulfonic acid. The sulfonyl chloride was filtered by suction filtration and washed with cold 
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water acetonitrile mixture. The resulting precipitate was considered pure enough to be used in 
subsequent reactions by TLC analysis.  
4.4. General Procedure for the Synthesis of Dibromo Chalcone Sulfonyl Chlorides 19–27 
The crude chalcone sulfonyl chloride 10–18 (10 g; 0.032 mol) was added to glacial acetic acid (125 
mL) with stirring. The resulting mixture was stirred at room temperature and to the stirred mixture 
was added bromine (20.48 g; 0.13 mol) dissolved in 50 mL glacial acetic acid. The mixture was stirred 
until a precipitate was formed which was filtered and washed with cold glacial acetic acid.  
4.5. General Procedure for the Synthesis of Benzothiazines 28–72 
To a stirred solution, at room temperature compounds 19–27, (1 g) in ethanol (25 mL) were 
added drop-wise to a primary amine (3 mol equivalent). The mixture was warmed on a water bath 
for 10–20 min making sure that the solvent does not evaporate. The mixture was then stirred at room 
temperature for a further half hour and then ice was added until a precipitate appeared. The resulting 
solid was filtered and allowed to dry overnight and recrystallized from the appropriate solvent. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(phenyl)methanone (28). 
Recrystallization solvent: ethanol; yield 68.7%; mp 203–204 °C; IR (KBr, ν·cm−1) 1688.9 (C=O), 1598.8 
(C-C, aromatic), 1329.6, 1146.2 (SO2). 1H-NMR (CDCl3): δ 3.87 (d, 1H), 3.93 (s, 3H, OCH3), 3.95 (s, 3H, 
OCH3), 4.51(d, 1H), 7.00–8.10 (m, 7H, Ar-H). 13C-NMR (CDCl3): δ 30.00, 46.00, 54.25, 56.51, 103.00, 
107.00, 112.50, 117.00, 120.00, 128.50, 134.00, 138.00, 149.00, 151.50, 192.10. HR-MS (nES) m/z calcd [M 
+ H]+ 346.0744: observed 346.0741. 
(6,7-Dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-
yl)(phenyl)methanone (29). Recrystallization solvent: ethanol; yield 79.5%; mp 190–192 °C. IR (KBr, 
ν·cm−1) 1598.1 (C=O), 1545.0 (C-C, aromatic), 1383.6, 1157.1 (SO2). 1H-NMR (CDCl3): δ 2.61 (d, 3H, 
CH3), 2.80 (s, 3H, CH3), 3.93 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 5.63(d, 1H), 6.80 (s, 1H), 7.24–7.79 (m, 
7H, Ar-H), 11.4 (broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR (CDCl3): δ 9.00, 11.00, 
30.10, 30.40, 32.10, 32.20, 55.10, 54.20, 101.00, 112.00, 113.00, 126.00, 126.40, 126.81, 128.37, 128.40, 
132.00, 160.00, 192.00. HR-MS (nES) m/z calcd [M + H]+ 391.1322: observed 391.1322. 
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(phenyl)methanone 
(30). Recrystallization solvent: ethanol; yield 93.0%; mp 200–201 °C. IR (KBr, ν·cm−1) 1693.5(C=O), 
1594.7 (C-C, aromatic), 1365.8, 1136.0 (SO2). 1H-NMR (CDCl3): δ 1.32 (t, 3H, CH3), 3.48 (q, 2H, CH2), 
3.68 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.12 (d, 1H, CH), 5.39 (d, 1H, CH), 6.68–7.92 (7H, Ar-H). 13C-
NMR (CDCl3): 13.20, 4594, 48.83, 56.20, 56.32, 62.85, 102.61, 108.00, 128.82, 128.90, 129.10, 130.00, 
134.10, 134.57, 150.75, 152.83, 193.70. HR-MS (nES) m/z calcd [M + H]+ 454.0318: observed 454.0316. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(phenyl)methanone 
(31). Recrystallization solvent: ethanol; yield 51.5%; mp 121–124 °C. IR (KBr, ν·cm−1) 1689.1 (C=O), 
1597.3 (C-C, aromatic), 1382.9, 1142.8 (SO2). 1H-NMR (CDCl3): δ 3.77 (s, 3H, OCH3), 4.02 (s, 3H, OCH3), 
5.759(d, 1H, CH), 7.04 (d, 1H, CH), 7.10–8.12 (m, 12H, Ar-H). 13C-NMR (CDCl3): δ 29.07, 43.56, 56.46, 
56.90, 11.25, 112.45, 121.40, 122.28, 125.30, 129.00, 129.03, 129.24, 130.10, 130.70, 134.20, 136.10, 148.20, 
152.25, 190.30. HR-MS (nES) m/z calcd [M + H]+ 502.0318: observed 502.0309. 
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(phenyl)methanone 
(32). Recrystallization solvent: ethanol; yield 91.8%; mp 133–134 °C. IR (KBr, ν·cm−1) 1685.7 (C=O), 
1589.7 (C-C, aromatic), 1359.9, 1145.8 (SO2). 1H-NMR (CDCl3): 3.90 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 
4.38 (d, 1H, CH2), 4.63 (d, 1H, CH2), 5.00 (d, 1H, CH), 5.37 (d, 1H, CH), 7.11–7.85 (12H, Ar-H). 13C-
NMR (CDCl3): δ 29.69, 48.50, 52.00, 56.38, 60.50, 98.50, 101.50, 109.00, 122.00, 123.50, 124.00, 128.12, 
128.13, 128.68, 128.90. 129.00, 134.00, 135.00, 136.5, 194.00.  
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-tolyl)methanone (33). 
Recrystallization solvent: ethanol; yield 50.6%; mp 176–177 °C. IR (KBr, ν·cm−1) 1681.6 (C=O), 1505.9 
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(C-C, aromatic), 1329.3, 1153.8 (SO2). 1H-NMR (CDCl3): δ 2.41 (s, 3H, CH3), 3.85 (d, 1H, CH), 3.92 (s, 
3H, OCH3), 3.95 (s, 3H, OCH3), 4.50 (d, 1H, CH), 7.00–8.99 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 21.84, 
29.68, 45.94, 55.50, 56.48, 104.18, 106.64, 125.00, 129.05, 129.21, 129.73, 146.00, 151.00, 154.00, 189.60.  
(6,7-Dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-
tolyl)methanone (34). Recrystallization solvent: ethanol; yield 79.7%; mp 183–184 °C. IR (KBr, ν·cm−1) 
1698.9 (C=O), 1575.0 (C-C, aromatic), 1383.0, 1161.1 (SO2). 1H-NMR (CDCl3): δ 2.34 (s, 3H, CH3), 2.59 
(s, 3H, CH3), 2.80 (d, 3H, CH3), 3.93 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.62 (d, 1H, CH), 6.81 (d, 1H, 
CH), 7.16–7.70 (m, 6H, Ar-H), 11.30, (broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR 
(CDCl3): δ 21.41, 29.16, 30.89, 31.66, 56.46, 56.47, 111.86, 112.71, 126.86, 129.00, 129.05, 137.50, 142.00, 
148.10, 152.00, 165.00, 188.10. HR-MS (nES) m/z calcd [M + H]+ 405.1479: observed 405.1474. 
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-tolyl)methanone 
(35). Recrystallization solvent: ethanol; yield 86.0%; mp 157–158 °C. IR (KBr, ν·cm−1) 1670.8 (C=O), 
1605.5 (C-C, aromatic), 1303.6, 1150.4 (SO2). 1H-NMR (CDCl3): δ 1.03 (t, 3H, CH3), 2.41 (s, 3H, CH3), 
3.34 (q, 2H, CH2), 3.94 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.05 (d, 1H, CH), 5.37 (d, 1H, CH), 7.17–7.91 
(6H, Ar-H). 13C-NMR (CDCl3): δ 12.77, 21.77, 29.68, 45.30, 47.56, 56.39, 61.73, 102.27, 109.15, 129.19, 
129.20, 129.74, 130.05, 132.00, 146.00, 151.80, 153.00, 192.80. HR-MS (nES) m/z calcd [M + H]+ 468.0475: 
observed 468.0472. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-tolyl)methanone 
(36). Recrystallization solvent: ethanol; yield 93.6%; mp 146–147 °C. IR (KBr, ν·cm−1) 1670.1 (C=O), 
1598.9 (C-C, aromatic), 1382.6, 1138.5 (SO2). 1H-NMR (CDCl3): δ 2.4 (s, 3H, CH3), 3.71 (d, 1H, CH), 3.75 
(s, 3H, OCH3), 4.00 (s, 3H, OCH3), 5.75 (d, 1H, CH), 7.09–8.01 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 
29.68, 44.00, 46.00, 56.49, 56.50, 112.00, 114.00, 122.13, 125.45, 129.14, 129.20, 129.21, 129.73, 134.05, 
145.40, 148.05, 152.34, 190.10. HR-MS (nES) m/z calcd [M + H]+ 516.0475: observed 516.0469. 
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(p-tolyl)methanone 
(37). Recrystallization solvent: ethanol; yield 94.8%; mp 151–152 °C. IR (KBr, ν·cm−1) 1680.3 (C=O), 
1606.9 (C-C, aromatic), 1315.7, 1149.1 (SO2). 1H-NMR (CDCl3): δ 2.36 (s, 3H, CH3), 3.89 (s, 3H, OCH3), 
3.96 (s, 3H, OCH3), 4.36 (d, 1H, CH2), 4.62 (d, 1H, CH2), 4.98 (d, 1H), 5.35 (d, 1H), 7.12–7.75 (m, 11H, 
Ar-H). 13C-NMR (CDCl3): δ 21.77, 29.69, 48.07, 51.18, 56.32, 56.37, 102.24, 108.91, 127.85, 128.67, 128.92, 
128.96, 129.12, 129.20, 130.10, 132.00, 135.07, 146.05, 151.10, 153.20, 192.45. HR-MS (nES) m/z calcd [M 
+ H]+ 530.0631: observed 530.0626. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-chlorophenyl)methanone 
(38). Recrystallization solvent: ethanol; yield 73.1%; mp 184–185 °C. IR (KBr, ν·cm−1) 1686.0 (C=O), 
1589.0 (C-C, aromatic), 1334.4, 1152.3 (SO2). 1H-NMR (CDCl3): δ 3.80 (s, 1H, CH), 3.93 (s, 3H, OCH3), 
3.95 (s, 3H, OCH3), 4.50 (d, 1H, CH), 7.00–8.06 (m, 6 H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 45.85, 55.43, 
56.51, 104.19, 106.64, 124.00, 128.00, 129.46, 130.49, 133.00, 141.00, 151.00, 154.00, 182.00. HR-MS (nES) 
m/z calcd [M − Br]+ 380.0354: observed 380.0356. 
(4-Chlorophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-
benzo[e][1,2]thiazin-3-yl)methanone (39). Recrystallization solvent: ethanol; yield 83.3%; mp 252–253 °C. 
IR (KBr, ν·cm−1) 1668.1 (C=O), 1541.2 (C-C, aromatic), 1381.2, 1144.7 (SO2). 1H-NMR (CDCl3): δ 2.60 (s, 
3H, CH3), 2.81 (d, 3H, NHCH3), 3.93 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 4.85 (broad singlet, 1H, NH 
(exchangeable with D2O), 5.57 (d, 1H, CH), 6.78 (d, 1H, CH), 7.24–7.71 (m, 6H, Ar-H). 13C-NMR 
(CDCl3): δ 29.60, 29.69, 32.00, 56.47, 56.49, 91.00, 111.06, 112.25, 127.00, 128.21, 128.57, 137.35, 138.56, 
149.34, 152.00, 163.00, 186.25. HR-MS (nES) m/z calcd [M + H]+ 425.0932: observed 425.0931. 
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
chlorophenyl)methanone (40). Recrystallization solvent: ethanol; yield 64.3%; mp 185–186 °C. IR (KBr, 
ν·cm−1) 1681.8 (C=O), 1589.9 (C-C, aromatic), 1364.5, 1136.0 (SO2). 1H-NMR (CDCl3): δ 1.26 (t, 3H, CH3), 
3.58 (q, 2H, CH2), 3.58 (d, 1H, CH), 3.82 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 5.13 (d, 1H, CH), 6.78–7.90 
Molecules 2016, 21, x  9 of 16 
(m, 6H, Ar-H). 13C-NMR (CDCl3): δ 13.48, 29.69, 39.54, 44.29, 56.28, 56.49, 102.47, 105.91, 127.00, 129.24, 
129.67, 131.85, 134.25, 140.05, 150.00, 153.75, 197.00.  
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
chlorophenyl)methanone (41). Recrystallization solvent: ethanol; Yield 76.8%; mp 162–164 °C. IR (KBr, 
ν·cm−1) 1689.4 (C=O), 1590.1 (C-C, aromatic), 1343.2, 1146.4 (SO2). 1H-NMR (CDCl3): δ 3.76 (s, 3H, 
OCH3), 4.01 (s, 3H, OCH3), 5.70 (d, 1H, CH), 7.10 (d, 1H, CH), 7.24–8.06 (m, 11H, Ar-H). 13C-NMR 
(CDCl3): δ 29.70, 43.70, 46.25, 56.02, 56.20, 112.20, 113.00, 122.00, 126.05, 129.20, 129.27, 129.42, 130.41, 
136.00, 141.25, 149.10, 153.70, 189.50. HR-MS (nES) m/z calcd [M + H]+ 535.9929: observed 535.9926. 
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
chlorophenyl)methanone (42). Recrystallization solvent: ethanol; yield 58.1%; mp 166–168 °C. IR (KBr, 
ν·cm−1) 1682.5 (C=O), 1589.0 (C-C, aromatic), 1357.9, 1146.9 (SO2). 1H-NMR (CDCl3): δ 3.92 (s, 3H, 
OCH3), 3.95 (s, 3H, OCH3), 4.35 (d, H, CH2), 4.57 (d, 1H, CH2), 4.92 (d, 1H), 5.48 (d, 1H), 7.10–7.77 (m, 
11H, Ar-H). 13C-NMR (CDCl3): 47.71, 51.71, 56.32, 56.37, 60.90, 102.28, 108.85, 128.12, 128.66, 128.90, 
129.67, 129.40, 130.33, 131.25, 132.80, 135.20, 141.20, 150.72, 152.29. 191.73. HR-MS (nES) m/z calcd [M 
+ H]+ 550.0085: observed 550.0082. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-bromophenyl)methanone 
(43). Recrystallization solvent: ethanol; yield 69.8%; mp 193–194 °C. IR (KBr, ν·cm−1) 1686.0 (C=O), 
1585.1 (C-C, aromatic), 1333.8, 1152.1 (SO2). 1H-NMR (CDCl3): δ 3.79 (d, 1H, CH), 3.93 (s, 3H, OCH3), 
3.95 (s, 3H, OCH3), 4.50 (d, 1H, CH), 7.00–7.97 (m, 6 H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 45.00, 54.50, 
56.51, 106.00, 106.05, 124.00, 127.00, 130.52, 130.60, 132.46, 133.00, 133.05, 154.00, 195.00. HR-MS (nES) 
m/z calcd [M − Br]+ 423.9849: observed 423.9850. 
(4-Bromo-6,7-dimethoxy-2-methyl-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
bromophenyl)methanone (44). Recrystallization solvent: ethanol; yield 78.8%; mp 189–190 °C. IR (KBr, 
ν·cm−1) 1677.3 (C=O), 1585.3 (C-C, aromatic), 1302.6, 1150.3 (SO2). 1H-NMR (CDCl3): δ 2.85 (s, 3H, 
CH3), 3.94 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 4.88 (d, 1H, CH), 5.31 (d, 1H, CH), 7.24–7.86 (m, 6 H, Ar-
H). 13C-NMR (CDCl3): δ 29.69, 37.38, 46.81, 56.45, 56.56, 102.66, 109.42128.50, 129.00, 129.50, 130.47, 
132.29, 133.10, 151.70, 152.00, 192.00.  
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
bromophenyl)methanone (45). Recrystallization solvent: ethanol; yield 86.3%; mp 171–172 °C. IR (KBr, 
ν·cm−1) 1676.6 (C=O), 1583.7 (C-C, aromatic), 1306.2, 1149.4 (SO2). 1H-NMR (CDCl3): δ 1.02 (t, 3H, CH3), 
3.33 (q, 2H, CH2), 3.95 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.02 (d, 1H, CH), 5.32 (d, 1H, CH), 7.11–7.87 
(m, 6H, Ar-H). 13C-NMR (CDCl3): δ 29.69, 45.20, 47.75, 56.90, 57.00, 62.00, 102.10, 108.80, 110.50, 112.30, 
130.20, 130.45, 132.40, 132.60, 151.80, 151.80, 152.10, 192.00. HR-MS (nES) m/z calcd [M + H]+ 517.9267: 
observed 517.9264. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
bromophenyl)methanone (46). Recrystallization solvent: ethanol; yield 89.5%; mp 218–219 °C. IR (KBr, 
ν·cm−1) 1688.7 (C=O), 1585.0 (C-C, aromatic), 1382.3, 1145.6 (SO2). 1H-NMR (CDCl3): δ 3.76 (s, 3H, 
OCH3), 4.01 (s, 3H, OCH3), 5.70 (d, 1H, CH), 7.05 (d, 1H, CH), 7.11–7.98 (m, 11H, Ar-H). 13C-NMR 
(CDCl3): δ 29.70, 43.45, 56.05, 56.40, 11.30, 112.10, 120.30, 120.45, 125.37, 127.35, 128.10, 128.45, 129.30, 
130.10, 132.10, 132.89, 148.37, 152.35, 189.75. HR-MS (nES) m/z calcd [M + H]+ 579.9423: observed 
579.9416. 
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
bromophenyl)methanone (47). Recrystallization solvent: ethanol; yield 80.6%; mp 176–177 °C. IR (KBr, 
ν·cm−1) 1685.5 (C=O), 1585.3 (C-C, aromatic), 1293.6, 1146.6 (SO2). 1H-NMR (CDCl3): δ 3.89 (s, 3H, 
OCH3), 3.96 (s, 3H, OCH3), 4.33 (d, 1H, CH2), 4.58 (d, 1H, CH2), 4.91 (d, 1H, CH), 5.28 (d, 1H, CH), 
7.09–7.70 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.95, 47.75, 51.45, 56.00, 60.24, 102.00, 108.50, 128.20, 
128.69, 128.94, 128.98, 130.39, 132.31, 132.70, 135.10, 135.20, 136.50, 150.50, 152.34, 192.00. HR-MS (nES) 
m/z calcd [M + H]+ 593.9580: observed 593.9579. 
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(6,7-Dimethoxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-3-yl)(4-fluorophenyl)methanone (48). 
Recrystallization solvent: ethanol; yield 58.0%; mp 249–250 °C. IR (KBr, ν·cm−1) 1638.2 (C=O), 1597.3 
(C-C, aromatic), 1363.4, 1152.7 (SO2). 1H-NMR (CDCl3): δ 3.93 (s, 3H, OCH3), 4.01 (s, 3H, OCH3), 6.86–
7.84 (m, 7H, Ar-H), 8.2 (broad singlet, 1H, NH (exchangeable with D2O). HR-MS (nES) m/z calcd [M 
+ H]+ 534.0381: observed 534.0376. 
(4-Bromo-6,7-dimethoxy-2-methyl-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
fluorophenyl)methanone (49). Recrystallization solvent: ethanol; yield 85.7%; mp 195–196 °C. IR (KBr, 
ν·cm−1) 1685.3 (C=O), 1598.0 (C-C, aromatic), 1325.1, 1146.5 (SO2). 1H-NMR (CDCl3): δ 2.10 (s, 3H, 
CH3), 3.90 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 4.84 (d, 1H, CH), 5.30 (d, 1H, CH), 7.10–8.00 (m, 6H, Ar-
H). 13C-NMR (CDCl3): δ 29.70, 37.25, 46.25, 56.44, 56.50, 103.56, 110.65, 116.15, 117.50, 128.00, 129.67, 
131.45, 132.00, 150.50, 152.00, 192.00. HR-MS (nES) m/z calcd [M + H]+ 458.0068: observed 458.0063. 
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
fluorophenyl)methanone (50). Recrystallization solvent: ethanol; yield 95.3%; mp 190–191 °C. IR (KBr, 
ν·cm−1) 1693.4 (C=O), 1598.3 (C-C, aromatic), 1345.8, 1185.0 (SO2). 1H-NMR (CDCl3): δ 3.92 (s, 3H, 
OCH3), 3.97 (s, 3H, OCH3), 5.50 (d, 1H, CH), 6.50 (d, 1H, CH), 6.85–8.10 (m, 6H, Ar-H). 13C-NMR 
(CDCl3): δ 16.00, 25.00, 29.70, 38.00, 43.50, 57.00, 110.05, 111.00, 117.00, 117.03, 117.05, 124.00, 131.76, 
131.790, 132.00, 164.00, 192.00. HR-MS (nES) m/z calcd [M + H]+ 472.0224: observed 472.0212. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
fluorophenyl)methanone (51). Recrystallization solvent: ethanol; yield 85.2%; mp 170–171 °C. IR (KBr, 
ν·cm−1) 1688.9 (C=O), 1598.8 (C-C, aromatic), 1382.7, 1146.8 (SO2). 1H-NMR (CDCl3): δ 3.76 (s, 3H, 
OCH3), 3.94 (s, 3H, OCH3), 5.71 (d, 1H, CH), 7.12 (d, 1H, CH), 7.24–8.16 (m, 11H, Ar-H). 13C-NMR 
(CDCl3): δ 29.45, 43.75, 56.34, 56.78, 11.10, 112.25, 116.10, 122.00, 122.30, 125.95, 129.30, 129.46, 130.00, 
130.80, 131.30, 131.57, 132.00, 152.40, 189.75. HR-MS (nES) m/z calcd [M + H]+ 520.0224: observed 
520.0218. 
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(4-
fluorophenyl)methanone (52). Recrystallization solvent: ethanol; yield 87.7%; mp 173–174 °C. IR (KBr, 
ν·cm−1) 1683.6 (C=O), 1596.9 (C-C, aromatic), 1356.5, 1147.3 (SO2). 1H-NMR (CDCl3): δ 3.90 (s, 3H, 
OCH3), 3.96 (s, 3H, OCH3), 4.38 (d, 1H, CH2), 4.60 (d, 1H, CH2), 4.98 (d, 1H, CH), 5.31 (d, 1H, CH), 
7.10–7.89 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.95, 47.96, 51.87, 56.21, 56.35, 102.35, 109.00, 116.20, 
116.25, 128.00, 128.67, 128.94, 130.05, 131.00, 131.50, 132.00, 135.10, 151.58, 152.00, 192.00. HR-MS (nES) 
m/z calcd [M + H]+ 534.0381: observed 534.0376. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-chlorophenyl)methanone 
(53). Recrystallization solvent: ethanol; yield 53.5%; mp 181–182 °C. IR (KBr, ν·cm−1) 1686.0 (C=O), 
1594.0 (C-C, aromatic), 1328.8, 1149.9 (SO2). 1H-NMR (CDCl3): δ 3.81 (d, 1H, CH), 3.94 (s, 3H, OCH3), 
3.96 (s, 3H, OCH3), 4.50 (d, 1H, CH), 7.01–8.04 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 45.95, 55.22, 56.51, 
56.85, 104.19, 106.65, 127.33, 128.33, 128.84, 129.50, 130.41, 134.51, 135.49, 136.40, 151.44, 154.07, 188.26.  
(3-Chlorophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-
benzo[e][1,2]thiazin-3-yl)methanone (54). Recrystallization solvent: ethanol; yield 77.0%; mp 176–177 °C. 
IR (KBr, ν·cm−1) 1600.9 (C=O), 1505.3 (C-C, aromatic), 1381.1, 1136.4 (SO2). 1H-NMR (CDCl3): δ 2.63 (s, 
3H,=3), 2.82 (s, 3H, CH3), 3.93 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 5.11 (d, 1H, CH), 5.55 (s, 1H, CH), 
6.77–7.66 (m, 6H, Ar-H), 11.28, (broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR (CDCl3): δ 
29.06, 30.25, 31.84, 56.48, 56.48, 90.98, 111.71, 112.81, 124.82, 126.97, 126.97, 129.57, 130.79, 135.25, 
142.00, 149.40, 153.45, 166.00, 186.00. HR-MS (nES) m/z calcd [M + H]+ 425.0932: observed 425.0927. 
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-
chlorophenyl)methanone (55). Recrystallization solvent: ethanol; yield 67.8%; mp 141–142 °C. IR (KBr, 
ν·cm−1) 1688.6 (C=O), 1590.7 (C-C, aromatic), 1300.1, 1143.6 (SO2). 1H-NMR (CDCl3): δ 1.04 (t, 3H, CH3), 
3.35 (q, 2H, CH2), 3.94 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.02 (d, 1H, CH), 5.32 (d, 1H, CH), 7.18–7.98 
(m, 6H, Ar-H). 13C-NMR (CDCl3): δ 12.65, 45.75, 47, 38, 56.43, 56.75, 61.71, 102.37, 109.07, 127.06, 
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129.03, 129.91, 130.33, 131.50, 132.50, 134.20, 134.70, 150.87, 152.34, 191.82. HR-MS (nES) m/z calcd [M 
+ H]+ 487.9929: observed 487.9923. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-
chlorophenyl)methanone (56). Recrystallization solvent: ethanol; yield 78.9%; mp 229–230 °C. IR (KBr, 
ν·cm−1) 1701.3 (C=O), 1595.8 (C-C, aromatic), 1337.2, 1140.8 (SO2). 1H-NMR (CDCl3): δ 3.84 (s, 3H, 
OCH3), 3.96 (s, 3H, OCH3), 5.40 (d, 1H, CH), 5.80 (d, 1H, CH), 6.90–7.42 (m, 11H, Ar-H). 13C-NMR 
(CDCl3): δ 47.90, 56.37, 56.90, 63.54, 102.97, 107.62, 125.74, 126.78, 128.74, 128.90, 129.78, 130.28, 131.50, 
132.00, 134.10, 134.20, 136.50, 138.00, 151.20, 153.12. HR-MS (nES) m/z calcd [M + H]+ 535.9929: 
observed 535.9925. 
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-
chlorophenyl)methanone (57). Recrystallization solvent: ethanol; yield 74.4%; mp 154–155 °C. IR (KBr, 
ν·cm−1) 1691.2 (C=O), 1591.8 (C-C, aromatic), 1335.9, 1138.2 (SO2). 1H-NMR (CDCl3): δ 3.90 (s, 3H, 
OCH3), 3.96 (s, 3H, OCH3), 4.40 (d, 1H, CH2), 4.57 (d, 1H, CH2), 4.97 (d, 1H, CH), 5.27 (d, 1H, CH), 
7.10–7.85 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 47.75, 51.78, 56.35, 56.39, 60.95, 102.31, 108.85, 126.50, 
127.69, 128.22, 128.70, 128.93, 130.19, 131.50, 134.17, 134.50, 134.70, 135.30, 135.50, 151.50, 152.10, 
192.00. HR-MS (nES) m/z calcd [M + NH4]+ 567.0351: observed 567.0345.  
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-bromophenyl)methanone 
(58). Recrystallization solvent: ethanol; yield 44.5%; mp 177–178 °C. IR (KBr, ν·cm−1) 1685.9 (C=O), 
1587.6 (C-C, aromatic), 1328.8, 1149.3 (SO2). 1H-NMR (CDCl3): δ 3.80 (d, 1H, CH), 3.93 (s, 3H, OCH3), 
3.95 (s, 3H, OCH3), 4.49 (d, 1H, CH), 7.00–8.19 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 29.95, 46.10, 55.10, 
56.51, 104.10, 106.80, 123.50, 126.40, 127.50, 128.10, 131.35, 131.86, 136.40, 137.24, 151.75, 153.95, 188.10. 
HR-MS (nES) m/z calcd [M + HBr]+ 423.9849: observed 423.9850. 
(3-Bromophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-
benzo[e][1,2]thiazin-3-yl)methanone (59). Recrystallization solvent: ethanol; yield 76.4%; mp 178–179 °C. 
IR (KBr, ν·cm−1) 1678.8 (C=O), 1570.4 (C-C, aromatic), 1311.2, 1136.4 (SO2). 1H-NMR (CDCl3): δ 2.63 (s, 
3H, CH3), 2.82 (d, 3H, NHCH3), 3.93 (s, 3H, OCH3), 3.97 (s, 3H, OCH3), 5.55 (d, 1H, CH), 6.77 (d, 1H, 
CH), 7.21–7.84 (m, 6H, Ar-H), 11.31 (broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR 
(CDCl3): δ 29.68, 29.80, 31.83, 56.49, 56.90, 91.20, 111.69, 112.20, 123.10, 125.32, 126.23, 128.10, 129.93, 
133.74, 141.35, 149.45, 152.00, 159.56, 186.34. HR-MS (nES) m/z calcd [M + H]+ 469.0427: observed 
469.0419. 
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-
bromophenyl)methanone (60). Recrystallization solvent: ethanol; yield 85.2%; mp 130–131 °C. IR (KBr, 
ν·cm−1) 1689.3 (C=O), 1590.2 (C-C, aromatic), 1350.4, 1142.9 (SO2). 1H-NMR (CDCl3): δ 1.02 (t, 3H, CH3), 
3.36 (q, 2H, CH2), 3.94 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.03 (d, 1H, CH), 5.32 (d, 1H, CH), 7.17–8.14 
(m, 6H, Ar-H). 13C-NMR (CDCl3): δ 12.64, 29.69, 45.74, 47.35, 56.43, 61.70, 101.70, 108.00, 122.10, 126.20, 
128.20, 130.05, 131.15, 136.05, 137.25, 138.15, 150.25, 152.15, 192.15. HR-MS (nES) m/z calcd [M + H]+ 
531.9423: observed 531.9421. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-
bromophenyl)methanone (61). Recrystallization solvent: ethanol; yield 80.2%; mp 232–233 °C. IR (KBr, 
ν·cm−1) 1701.6 (C=O), 1595.3 (C-C, aromatic), 1284.2, 1141.5 (SO2). 1H-NMR (CDCl3): δ 3.85 (s, 3H, 
OCH3), 3.91 (s, 3H, OCH3), 5.45 (d, 1H, CH), 5.80 (d, 1H, CH), 6.80–7.94 (m, 11H, Ar-H). 13C-NMR 
(CDCl3): δ 51.93, 56.24, 56.38, 56.48, 62.06, 102.53, 108.04, 127.33, 127.43, 128.17, 129.18, 129.40, 130.03, 
132.67, 133.84, 134.86, 138.10, 150.96, 152.97, 196.11. HR-MS (nES) m/z calcd [M + NH4]+ 596.9689: 
observed 596.9685. 
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(3-
bromophenyl)methanone (62). Recrystallization solvent: ethanol; Yield 96.9%; mp 167–168 °C. IR (KBr, 
ν·cm−1) 1690.8 (C=O), 1590.8 (C-C, aromatic), 1334.6, 1137.9 (SO2). 1H-NMR (CDCl3): δ 3.90 (s, 3H, 
OCH3), 3.91 (s, 3H, OCH3), 4.40 (d, 1H, CH2), 4.56 (d, 1H, CH2), 4.97 (d, 1H, CH), 5.26 (d, 1H, CH), 
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7.10–7.96 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.69, 47.72, 56.35, 56.39, 60.97, 102.31, 108.85, 122.80, 
127.40, 127.75, 128.24, 128.60, 128.71, 128.93, 130.41, 131.89, 135.10, 136.20, 137.25, 151.45, 152.10, 
192.23. HR-MS (nES) m/z calcd [M + NH4]+ 610.9845: observed 610.9842. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-chlorophenyl)methanone 
(63). Recrystallization solvent: ethanol; yield 72.8%; mp 185–186 °C. IR (KBr, ν·cm−1) 1696.5 (C=O), 
1677.0 (C-C, aromatic), 1337.3, 1153.7 (SO2). 1H-NMR (CDCl3): δ 3.80 (d, 1H, CH), 3.91 (s, 3H, OCH3), 
3.95 (s, 3H, OCH3), 4.41 (d, 1H, CH), 6.97–7.53 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 47.50, 56.49, 
56.51, 104.00, 106.00, 122.00, 125.00, 126.50, 130.79, 133.90, 147.50, 153.50, 160.0, 161.90, 192.00.  
(2-Chlorophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4dihydro-2H-benzo[e][1,2]thiazin-
3-yl)methanone (64). Recrystallization solvent: ethanol; yield 65.4%; mp 118–119 °C. IR (KBr, ν·cm−1) 
1602.0 (C=O), 1568.8 (C-C, aromatic), 1309.7, 1147.6 (SO2). 1H-NMR (CDCl3): δ 2.56 (s, 3H, CH3), 2.81 
(s, 3H, CH3), 3.92 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 4.91 (d, 1H, CH), 5.26 (s, 1H, CH), 7.24–7.52 (m, 
6H, Ar-H), 6.76, (broad singlet, 1H, NH. 13C-NMR (CDCl3): δ 27.80, 32.00, 56.50, 57.50, 95.00, 101.00, 
101.90, 111.00, 112.00, 126.00, 127.00, 129.92, 130.00, 131.00, 132.00, 164.00, 190.00. HR-MS (nES) m/z 
calcd [M + H]+ 425.0932: observed 425.0928. 
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-
chlorophenyl)methanone (65). Recrystallization solvent: ethanol; yield 48.2%; mp 129–131 °C. IR (KBr, 
ν·cm−1) 1701.3 (C=O), 1589.9 (C-C, aromatic), 1383.4, 1141.1 (SO2). 1H-NMR (CDCl3): δ 1.31 (t, 3H, CH3), 
3.44 (q, 2H, CH2), 3.82 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 5.29 (d, 1H, CH), 5.44 (d, 1H, CH), 6.86–7.74 
(m, 6H, Ar-H). 13C-NMR (CDCl3): δ 45.04, 51.63, 52.98, 56.01, 61.49, 62.44, 102.36, 10258, 108.08, 108.72, 
127.04, 127.09, 127.68, 130.93, 132.95, 150.85, 152.44, 152.92, 193.34. HR-MS (nES) m/z calcd [M + H]+ 
487.9927: observed 487.9918. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-
chlorophenyl)methanone (66). Recrystallization solvent: ethanol; yield 84.2%; mp 209–210 °C. IR (KBr, 
ν·cm−1) 1710.0 (C=O), 1587.7 (C-C, aromatic), 1304.6, 1144.7 (SO2). 1H-NMR (CDCl3): δ 3.96 (s, 3H, 
OCH3), 3.98 (s, 3H, OCH3), 5.52 (d, 1H, CH), 5.80 (d, 1H, CH), 6.80–7.94 (m, 11H, Ar-H). 13C-NMR 
(CDCl3): δ 29.70, 52.05, 56.42, 56.46, 102.45, 108.20, 126.36, 126.78, 127.14, 127.56, 127.85, 128.45, 129.56, 
130.04, 132.05, 133.56, 137.34, 136.00, 150.78, 153.45, 196.67. HR-MS (nES) m/z calcd [M + H]+ 535.9929 
535: observed 535.9924. 
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-
chlorophenyl)methanone (67). Recrystallization solvent: ethanol; yield 90.8%; mp 156–157 °C. IR (KBr, 
ν·cm−1) 1692.5 (C=O), 1592.0 (C-C, aromatic), 1342.2, 1140.2 (SO2). 1H-NMR (CDCl3): δ 3.89 (s, 3H, 
OCH3), 3.95 (s, 3H, OCH3), 4.45 (d, 1H, CH2), 4.70 (d, 1H, CH2), 5.05 (d, 1H, CH), 5.28 (d, 1H, CH), 
7.01–7.42 (m, 11H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 50.75, 52.52, 56.38, 60.45, 102.34, 108.25, 126.50, 
127.34, 128.50, 128.78, 129.04, 129.42, 130.87, 131.50, 132.23, 135.60, 135.80, 136.00, 150.70, 152.10, 
194.00. HR-MS (nES) m/z calcd [M + NH4]+ 567.0351: observed 567.0342. 
(4-Bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-bromophenyl)methanone 
(68). Recrystallization solvent: ethanol; yield 56.6%; mp 183–184 °C. IR (KBr, ν·cm−1) 1696.7 (C=O), 
1676.3 (C-C, aromatic), 1336.3, 1153.2 (SO2). 1H-NMR (CDCl3): δ 3.85 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 
5.45 (d, 1H, CH), 5.78 (d, 1H, CH) 6.98–7.93 (m, 6H, Ar-H). 13C-NMR (CDCl3): δ 29.70, 47.96, 56.41, 
63.53, 102.97, 107.62, 124.10, 125.74, 127.21, 128.00, 129.79, 130.50, 131.65, 137.26. 138.05, 150.12, 190.45. 
HR-MS (nES) m/z calcd [M − Br]+ 423.9849: observed 423.9849. 
(2-Bromophenyl)(6,7-dimethoxy-2-methyl-4-(methylamino)-1,1-dioxido-3,4-dihydro-2H-
benzo[e][1,2]thiazin-3-yl)methanone (69). Recrystallization solvent: ethanol; yield 75.2%; mp 122–123 °C. 
IR (KBr, ν·cm−1) 1737.9 (C=O), 1655.7 (C-C, aromatic), 1383.0, 1147.1 (SO2). 1H-NMR (CDCl3): δ 2.55 (s, 
3H, CH3), 2.83 (s, 3H, CH3), 3.93 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 4.80 (d, 1H, CH), 5.16 (s, 1H, CH), 
6.77–7.53 (m, 6H, Ar-H), 11.35, (broad singlet, 1H, NH (exchangeable with D2O). 13C-NMR (CDCl3): δ 
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29.31, 29.78, 31.82, 56.51, 56.58, 94.73, 11.70, 112.76, 118.00, 127.44, 128.79, 129.40, 130.21, 130.75, 133.01, 
143.45, 148.12, 151.75, 164.91, 192.30. HR-MS (nES) m/z calcd [M + H]+ 469.0427: observed 469.0418. 
(4-Bromo-2-ethyl-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-
bromophenyl)methanone (70). Recrystallization solvent: ethanol; yield 69.3%; mp 129–130 °C. IR (KBr, 
ν·cm−1) 1689.5 (C=O), 1590.1 (C-C, aromatic), 1350.4, 1142.8 (SO2). 1H-NMR (CDCl3): δ 1.05 (t, 3H, CH3), 
3.35 (q, 2H, CH2), 3.89 (s, 3H, OCH3), 3.95 (s, 3H, OCH3), 5.03 (d, 1H, CH), 5.29 (d, 1H, CH), 7.19–8.15 
(m, 6H, Ar-H). 13C-NMR (CDCl3): 12.64, 45.73, 47.34, 56.35, 56.41, 61.69, 102.35, 109.05, 123.37, 127.48, 
129.89, 130.53, 131.94, 132.20, 136.00, 137.08, 150.85, 152.32, 191.72.  
(4-Bromo-6,7-dimethoxy-1,1-dioxido-2-phenyl-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-
bromophenyl)methanone (71). Recrystallization solvent: ethanol; yield 96.8%; mp 210–211 °C. IR (KBr, 
ν·cm−1) 1709.5 (C=O), 1588.1 (C-C, aromatic), 1305.1, 1144.7 (SO2). 1H-NMR (CDCl3): δ 3.96 (s, 3H, 
OCH3), 3.98 (s, 3H, OCH3), 5.52 (d, 1H, CH), 5.79 (d, 1H, CH), 7.24–7.62 (m, 11H, Ar-H). 13C-NMR 
(CDCl3): δ 29.69, 51.96, 56.42, 56.51, 102.45, 108.23, 119.50, 126.60, 126.85, 127.25, 127.45, 128.85, 128.95, 
130.06, 132.32, 132.85, 134.23, 138.45, 151.50, 151.80, 196.10. HR-MS (nES) m/z calcd [M + H]+ 579.9423: 
observed 579.9423. 
(2-Benzyl-4-bromo-6,7-dimethoxy-1,1-dioxido-3,4-dihydro-2H-benzo[e][1,2]thiazin-3-yl)(2-
bromophenyl)methanone (72). Recrystallization solvent: ethanol; yield 81.6%; mp 123–125 °C. IR (KBr, 
ν·cm−1) 1690.6 (C=O), 1590.4 (C-C, aromatic), 1334.3, 1137.9 (SO2). 1H-NMR (CDCl3): δ 3.89 (s, 3H, 
OCH3), 3.96 (s, 3H, OCH3), 4.39 (d, 1H, CH2), 4.55 (d, 1H, CH2), 4.97 (d, 1H, CH), 5.27 (d, 1H, CH), 
7.10–7.96 (m, 11H, Ar-H). 13C-NMR (CDCl3): 47.72, 51.74, 56.34, 56.38, 60.97, 102.30, 108.83, 123.80, 
127.37, 128.21, 128.68, 128.89, 130.40, 131.85, 135.00, 135.60, 140.10, 150.74, 152.32, 191.62. HR-MS (nES) 
m/z calcd [M + H]+ 593.9580: observed 593.9578.  
4.6. Antimicrobial Activity 
For determining the antibacterial activities, the synthesized compounds were dissolved in 
DMSO (20 mg/mL). Broth dilution method in a 96 wells micro-titre plate was used to test the 
compounds (27–72) [6]. Mueller Hinton Broth was used as diluents in the wells of the micro-titre 
plate. The dilutions were prepared at the required quantities of 600, 500, 400, 200, 100, 50, 25, 12.5 
µg/mL. Equal volume of bacterial culture was added to it after comparing it with 0.5 McFarland 
standard and incubated at 37 °C for 16 to 18 h on a rotary shaker at 150 rpm [39]. Plates were then 
examined for the turbidity as an indicator of growth and the absorbance was taken with the help of 
ELISA reader at 590 nm [40]. First well that appeared having zero absorbance was taken to be the 
MIC (Minimum inhibitory concentration) [8]. This was followed by an MTT assay for confirmation. 
Streptomycin was used as a reference control at concentrations of 50, 25, 12.5, 6.25, 3.12, 1.56, 0.78, 
0.39 µg/mL. Streptomycin is a broad spectrum antibiotic which inhibits the growth of both Gram-
positive and Gram-negative bacteria and has been widely used as a reference [41,42]. In order to 
ensure that the solvent had no effect on bacterial growth, a control test was also performed containing 
inoculated broth supplemented with different concentrations (1%–16%) of DMSO. All the tests were 
performed in triplicates.  
The MBC (minimum bactericidal concentration) was determined by sub culturing the 
preparations that have shown no evidence of growth on Mueller Hinton Agar in neat and dilutions 
of 1:10 and 1:100. A colony-forming unit (CFU) count was done for the agar plates and the dilution 
that gave 99.9% reduction to the original inoculum was considered to be the MBC. 
All the compounds were tested for their in vitro growth inhibitory activity against different 
bacteria. The bacterial strains used were Bacillus subtilis ATCC 6633 and Staphylococcus aureus ATCC 
6538 as Gram-positive bacteria and Salmonella typhimurium ATCC 14028 (Salmonella enterica) and 
Proteus vulgaris ATCC 13315 as Gram-negative bacteria. Staphylococcus aureus is a clinically important 
pathogen as it causes various types of infections [43] and Bacillus subtilis was used as a model 
organism as it belongs to the same group as pathogenic Bacillus anthracis species [44]. Salmonella 
typhimurium is clinically important as it can cause enteritis. Proteus vulgaris has been isolated from 
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long term care facilities and hospitals and from immunocompromised patients. The strains used in 
this study were obtained from culture collection of University of Hertfordshire. 
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